Citadel Advisors
XFOR icon

Citadel Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Citadel Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-680
Closed -$4.82K – 15394
2025
Q1 		$4.82K Sell
680
-1,080
-61% -$14.9K ﹤0.01% 13862
2024
Q4 		$38.7K Buy
1,760
+1,020
+138% +$16.3K ﹤0.01% 12641
2024
Q3 		$14.9K Sell
740
-97
-12% -$2.02K ﹤0.01% 13004
2024
Q2 		$14.6K Sell
837
-1,630
-66% -$53.3K ﹤0.01% 12875
2024
Q1 		$103K Buy
2,467
+647
+36% +$18K ﹤0.01% 11322
2023
Q4 		$45.8K Sell
1,820
-2,693
-60% -$65.5K ﹤0.01% 11864
2023
Q3 		$148K Sell
4,513
-1,620
-26% -$70.7K ﹤0.01% 10384
2023
Q2 		$357K Buy
6,133
+2,643
+76% +$136K ﹤0.01% 8661
2023
Q1 		$91.1K Sell
3,490
-1,117
-24% -$32.8K ﹤0.01% 11396
2022
Q4 		$137K Buy
4,607
+1,580
+52% +$74.8K ﹤0.01% 10744
2022
Q3 		$155K Buy
3,027
+1,954
+182% +$67.5K ﹤0.01% 10667
2022
Q2 		$31K Sell
1,073
-1,040
-49% -$39.6K ﹤0.01% 12207
2022
Q1 		$111K Sell
2,113
-184
-8% -$10.6K ﹤0.01% 12177
2021
Q4 		$158K Buy
2,297
+1,920
+509% +$243K ﹤0.01% 12202
2021
Q3 		$60K Buy
+377
New +$62K ﹤0.01% 13269

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's XFOR Position: Q1 2026 in Review

Citadel Advisors sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 128,675 shares — an estimated $515K sold.

Citadel Advisors first reported a position in XFOR in Q1 2020 and held it in 14 quarters. The position peaked at $5.96M in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Citadel Advisors reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 128,675 X4 Pharmaceuticals shares in Q1 2026, an estimated $515K.
  • Citadel Advisors first reported a position in X4 Pharmaceuticals in Q1 2020 and held it in 14 quarters.
  • Citadel Advisors's X4 Pharmaceuticals position peaked at $5.96M in Q2 2023.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.